GlaxoSmithKline/ Boehringer
AstraZeneca and GSK Join Boehringer Ingelheim in Capping Out-of-Pocket Inhaler Costs at $35 per Month
AstraZeneca/ GlaxoSmithKline/ Boehringer Ingelheim/ inhaler/ out-of-pocket costs/ cap/ $35/ asthma/ COPD/ price reduction/ drug pricing/ U.S./ congressional scrutiny/ patient affordability/ medication accessibility.